Yingtai Chen (Chen Yingtai)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 5

Top Topics

Simultaneous Determination

Artificial Intelligence

Top Venues

Journal of oncology

International journal of surgery (London, England)

Journal of translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Xianchun Gao, Lulu Zhao, Nannan Zhang, Weili Han, Kun Liu, Junya Yan, Ling Chen, Yan Pan, Renlong Li, Wenjiao Li, Haohao Zhang, Hongwei Li, Shibo Wang, Xiaoliang Gao, Penghui Niu, Wanqing Wang, Gang Ji, Qingchuan Zhao, Yuanyuan Lu, Zengshan Li, Lei Shang, Han Liang, Kaichun Wu, Jingyu Deng, Yingtai Chen, Yongzhan Nie, null null
Impact of HER2 on prognosis and benefit from adjuvant chemotherapy in stage II/III gastric cancer patients: a multicenter observational study. International journal of surgery (London, England) (2023)
Xiaoyi Luan, Penghui Niu, Wanqing Wang, Lulu Zhao, Xiaojie Zhang, Dongbing Zhao, Yingtai Chen
Sex Disparity in Patients with Gastric Cancer: A Systematic Review and Meta-Analysis. Journal of oncology 2022 (2022)
Penghui Niu, Huang Huang, Lulu Zhao, Tongbo Wang, Xiaojie Zhang, Wanqing Wang, Yawei Zhang, Chunguang Guo, Dongbing Zhao, Yingtai Chen
Clinicopathological characteristics, survival outcomes, and genetic alterations of younger patients with gastric cancer: Results from the China National Cancer Center and cBioPortal datasets. Cancer medicine 11 (16) (2022)
Yingtai Chen, Jianhua Yin, Lulu Zhao, Guangyu Zhou, Shichen Dong, Yueming Zhang, Penghui Niu, Hu Ren, Tianjiao Zheng, Juan Yan, Wenbin Li, Peiqin Ma, Cuijuan Zhang, Chen Wei, George Church, Guibo Li, Dongbing Zhao
Reconstruction of the gastric cancer microenvironment after neoadjuvant chemotherapy by longitudinal single-cell sequencing. Journal of translational medicine 20 (1) (2022)
Lulu Zhao, Weili Han, Xisheng Yang, Dongbing Zhao, Penghui Niu, Xianchun Gao, Zhenkun Wu, Xiaojie Zhang, Zefeng Li, Gang Ji, Yingtai Chen
Exceeding 30 ELNs is strongly recommended for pT3-4N0 patients with gastric cancer: A multicenter study of survival, recurrence, and prediction model. Cancer science 112 (8) (2021)